Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
275 participants
OBSERVATIONAL
2020-07-01
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Waxing and Waning of Serum SARS CoV-2-IgG Level in COVID-19 Exposed Population
NCT04568850
Antibodies Responses to COVID-19 Infection in Hospitalized Patients
NCT04520880
Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays
NCT04562285
SARS-CoV-2 IgG and IgM Serologic Assays
NCT04562246
Monitoring the IgG/IgM Antibodies in COVID-19 Patients
NCT04810117
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The seropositivity rate of both IgM and IgG responses after onset and recovery of disease, and in the context of both N protein and S protein has not been clarified. The kinetics of antibody responses in critical cases or ICU patients has not been reported, and no studies have suggested whether antibody response is associated with disease prognosis
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IgG SARS CoV2
IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lahore General Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amina Asif
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amina Asif, MPhilMicro
Role: PRINCIPAL_INVESTIGATOR
LahoreGeneralHospital.Lahore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lahore General Hospital
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LGH006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.